Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Attorneys Expect COVID-19 ‘Enforcement Press’ Centered On PREP Act, Diagnostics

Executive Summary

Three attorneys got out their crystal balls to forecast what device industry sectors may come in for enforcement scrutiny related to the COVID-19 pandemic.

You may also be interested in...



Federal Jury Convicts Medtech President In COVID-19 And Allergy Testing Scheme

Arrayit president Mark Schena was convicted of conspiracy to commit healthcare fraud using the company's allergy and COVID-19 tests.

14 Health Care Professionals Ensnared In DOJ COVID-19 Fraud Enforcement

The crackdown, which was executed by the US DOJ’s new COVID-19 fraud task force, involves false claims in six states worth more than $143m.

Device Exec Charged With COVID-19 Securities Fraud

The CEO allegedly falsely told investors that the company was closing in on FDA clearance for a rapid-detection COVID-19 test.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT143325

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel